Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 24, 2008

XDx to Restructure

  • XDx is reprioritizing its business efforts. The firm will increase its research, development, and commercial activities in support of AlloMap®. In addition, it will restructure its internal development program, pursue external research collaborations in lupus, as well as suspend development activities in lung transplant. A staff reduction of 25 positions and other cost-saving measures will be undertaken as well.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »